GKC has successfully secured funding from the high profile and leading international funder in Parkinson's - The Michael J. Fox Foundation as well as the Shake It Up Australia Foundation and Parkinson's Victoria, to support a global trial to evaluate the use of objective targets to guide the treatment and management of Parkinson's disease.
Please read the full press release here
Reported in Nature's npj Parkinson's Disease, the study demonstrates the use of objective targets and measurement with the PKG system significantly improved clinical care and quality of life for people with Parkinson's.
Key findings of the study were that most people with PD (78%) are living with symptoms considered to be outside the target range including excessive bradykinesia, dyskinesia and tremor. Using targets and objective assessment, clinicians were able to improve treatment options in more than half of the study participants.
To read the full article, please click here
GKC's President and CEO, John Schellhorn, and Senior VP Business Development and Legal Affairs, Michelle Goldsmith, will attend the 2018 J.P. Morgan Healthcare Conference in San Francisco, CA in January.
GKC has received notification of issuance by the US patent office of a patent covering its key product the Personal KinetiGraph™ (PKG™).
The October edition of the Dutch Parkinson Magazine, published by the Dutch Parkinson's disease Association, highlighted an interview with Anne van der Plas, neurologist at the Alrijne hospital in the Netherlands.
The interview describes how the PKG is used in their hospital and the benefits to both clinicians and patients.
GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors.
Schellhorn joins GKC with a proven track record to spearhead the company's accelerated growth strategy to meet the demand for its lead product, the PKG™ system.
